Comments
Drug firm Strides Pharma Science on Friday reported a consolidated profit after tax of ₹43.81 crore from operations for the March 2019 quarter.
The company had posted a loss of ₹3.39 crore in the year-ago period, the company said in a BSE filing.
Consolidated revenue stood at ₹839.70 crore for the quarter under review as against ₹669.89 crore for the same period a year ago.
For 2018-19, the company posted a profit after tax of ₹58.93 crore compared to ₹74.27 crore in 2017-18.
The company’s consolidated revenue from operations stood at ₹3,011.68 crore for 2018-19, against ₹2,845.12 crore in the year-ago period.
“Starting the year with several challenges, we are satisfied with our FY19 exit quarter performance as most of the strategic outcomes have met our expectations,” Strides Pharma Science founder and group CEO Arun Kumar said.
Moving into the new financial year, company’s emerging market and institutional business will get highest attention and priority, he added.
The company said its board has proposed a final dividend of ₹3 per equity share of face value of ₹10 each.
Shares of Strides Pharma Science closed at ₹485.70 per scrip on the BSE, up 0.37 per cent from its previous close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.